We currently represent several high quality biotech companies in multi-track licensing and M&A engagements, including:

  • A company with an immunotherapy technology for anti-viral therapy with a lead compound focused on curing HBV, available for licensing and financing
  • A company with a PhII ready compound for the treatment of autoimmune disorders and AMI, available for licensing and financing
  • A company with a near to market hospital IM/IV CNS asset, available for licensing, and also seeking financing
  • A company with an asset in a registration trial  with orphan drug designation issued in the US for PTCL, CTCL and neuroblastoma and pending in EU, available for licensing
  • A company with a pediatric asset to treat IgA Nephropathy, and orphan renal disorder, with orphan designation, available for licensing
  • A company with a novel GI asset for the treatment of short bowel syndrome, with orphan drug designation, available for licensing.
Geller Biopharm

  Broker / Dealer services provided by Pickwick Capital Partners, LLC. Member FINRA / SIPC



Download our presentation
PDF

Get a digital copy of our PDF presentation

Download PDF